Types of Cancer

Rubraca Significantly Improves Survival Ovarian Cancer (01-18-2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading

Xgeva Approved for The Treatment of Multiple Myeloma (01-17-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (01-17-2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy (01-16-2018)

CancerConnect News:  All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer (01-15-2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified... Continue Reading

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (01-15-2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients (01-15-2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (01-14-2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma (01-12-2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment... Continue Reading

FDA approves Gazyva for previously untreated follicular lymphoma (01-11-2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment... Continue Reading

Next Page »